Panbela Therapeutics (NASDAQ: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, has released the pricing of its public offering. The public offering is comprised of 20,100,000 shares of its common stock (or prefunded warrants in lieu thereof); the announcement also reported on the pricing of warrants for the purchase of up to 30,150,000 shares of common stock. The offering closed on Oct. 4, 2022. The purchase price was $0.30 per share and associated public warrant. The announcement outlined key information regarding the public warrants: they will have an exercise price of $0.30 per share, are exercisable upon issuance, and will expire five years following the date of issuance. Roth Capital Partners acted as lead placement agent for the offering.
To view the full press release, visit https://ibn.fm/cxwBX
About Panbela Therapeutics Inc.
Panbela Therapeutics is a clinical-stage biopharmaceutical company developing disruptive therapeutics for patients with urgent unmet medical needs. Panbela’s lead assets are Ivospemin (SBP- 101) and Flynpovi. For more information about the company, please visit www.Panbela.com.
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.
As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@InvestorWire.com
InvestorWire is part of the InvestorBrandNetwork.
